Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
While there is some evidence to suggest that GLP-1 agonists may have health benefits beyond their approved use for type 2 diabetes and obesity, non-diabetics should not take these medications without a prescription and guidance from a healthcare professional
doi: 10.1016/j.bcp.2020.114187, 130 SanfordM
This is a practical consideration for the dosage comparison
Ozempic & Deep Vein Thrombosis (DVT) / Blood Clot Risks February 20, 2024, Ernie Mundell, GLP-1 Meds May Lower Clot Risk in People With Diabetes, Dec 10, 2024, American Heart Association Scientific Sessions, GLP-1, SGLT2 medications may lower stroke survivors risk of future heart attack, stroke2024, Abstract 4148007 Roua Anamaria Iorga, Nicolae Bacalbasa, Mara Carsote, Ovidiu Gabriel Bratu, Ana Maria Alexandra Stanescu, Simona Bungau, Carmen Pantis, Camelia Cristina Diaconu, Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review) Exp Ther Med 2020 May 5;20(3):23962400.
Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use Wegovy (semaglutide) tablets, for oral use
